☰

Elspeth M. Beauchamp, Ph.D. - Publications

Affiliations: 
2010 Tumor Biology Georgetown University, Washington, DC 
Area:
Oncology, Cell Biology, Biochemistry
Tree Info Similar researchers PubMed Report error

28/44 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Saleiro D, Kosciuczuk EM, Fischietti M, Perez RE, Yang GS, Eckerdt F, Beauchamp EM, Hou Y, Wang Q, Weinberg RS, Fish EN, Yue F, Hoffman R, Platanias LC. Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells. Cancer Research Communications. 3: 943-951. PMID 37377894 DOI: 10.1158/2767-9764.CRC-23-0010  0.354
2022 Fischietti M, Eckerdt F, Perez RE, Guillen Magaña JN, Mazewski C, Ho S, Gonzalez C, Streich LD, Beauchamp EM, Heimberger AB, Baran AH, Yue F, James CD, Platanias LC. SLFN11 negatively regulates non-canonical NFkB signaling to promote glioblastoma progression. Cancer Research Communications. 2: 966-978. PMID 36382088 DOI: 10.1158/2767-9764.crc-22-0192  0.367
2021 Suarez M, Blyth GT, Mina AA, Kosciuczuk EM, Dolniak B, Dinner S, Altman JK, Eklund EA, Saleiro D, Beauchamp EM, Platanias LC. Inhibitory effects of Tomivosertib in acute myeloid leukemia. Oncotarget. 12: 955-966. PMID 34012509 DOI: 10.18632/oncotarget.27952  0.304
2021 Fischietti M, Eckerdt F, Blyth GT, Arslan AD, Mati WM, Oku CV, Perez RE, Lee-Chang C, Kosciuczuk EM, Saleiro D, Beauchamp EM, Lesniak MS, Verzella D, Sun L, Fish EN, et al. Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma. Oncogene. PMID 33846574 DOI: 10.1038/s41388-021-01761-1  0.355
2021 Eisfelder BJ, Saygin C, Wynne J, Colton MW, Fischietti M, Beauchamp EM, Cheng JX, Odenike O, Roboz G, Alachkar H, Stock W. OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. Blood Cancer Journal. 11: 48. PMID 33658483 DOI: 10.1038/s41408-021-00433-3  0.31
2019 Kosciuczuk EM, Kar AK, Blyth GT, Fischietti M, Abedin S, Mina AA, Siliezar R, Rzymski T, Brzozka K, Eklund EA, Beauchamp EM, Eckerdt F, Saleiro D, Platanias LC. Inhibitory effects of SEL201 in acute myeloid leukemia. Oncotarget. 10: 7112-7121. PMID 31903169 DOI: 10.18632/Oncotarget.27388  0.35
2019 Eckerdt F, Clymer J, Bell JB, Beauchamp EM, Blyth GT, Goldman S, Platanias LC. Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma. Scientific Reports. 9: 12822. PMID 31492956 DOI: 10.1038/S41598-019-49299-3  0.417
2019 Eckerdt F, Bell JB, Beauchamp EM, Clymer J, Blyth GT, Kosciuczuk EM, Ma Q, Chen DZ, Horbinski C, Goldman S, Munshi HG, Hashizume R, Platanias LC. Potent Antineoplastic Effects of Combined PI3Kα-MNK Inhibition in Medulloblastoma. Molecular Cancer Research : McR. PMID 30842251 DOI: 10.1158/1541-7786.Mcr-18-1193  0.428
2018 Beauchamp EM, Abedin SM, Radecki SG, Fischietti M, Arslan AD, Blyth GT, Yang A, Lantz C, Nelson A, Goo YA, Akpan I, Eklund EA, Frankfurt O, Fish EN, Thomas PM, et al. Identification and targeting of novel CDK9 complexes in acute myeloid leukemia. Blood. PMID 30587525 DOI: 10.1182/Blood-2018-08-870089  0.302
2017 Bell JB, Eckerdt F, Dhruv H, Finlay D, Peng S, Kim S, Kroczynska B, Beauchamp E, Alley K, Clymer J, Goldman S, Cheng SY, James CD, Nakano I, Horbinski C, et al. Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy is Regulated by MNK1 and mRNA Translation. Molecular Cancer Research : McR. PMID 29042487 DOI: 10.1158/1541-7786.Mcr-17-0397  0.334
2015 Terai H, Tan L, Beauchamp EM, Hatcher JM, Liu Q, Meyerson M, Gray NS, Hammerman PS. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer. Acs Chemical Biology. PMID 26390252 DOI: 10.1021/Acschembio.5B00655  0.341
2015 Xu C, Buczkowski KA, Zhang Y, Asahina H, Beauchamp EM, Terai H, Li YY, Meyerson M, Wong KK, Hammerman PS. NSCLC Driven by DDR2 Mutation is Sensitive to Dasatinib and JQ1 Combination Therapy. Molecular Cancer Therapeutics. PMID 26206333 DOI: 10.1158/1535-7163.Mct-15-0077  0.313
2015 Colamonici M, Blyth G, Saleiro D, Szilard A, Bliss-Moreau M, Giles FJ, Altman JK, Beauchamp EM, Platanias LC. Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase. Oncotarget. 6: 8062-70. PMID 25823922 DOI: 10.18632/Oncotarget.3509  0.306
2015 Beauchamp EM, Kosciuczuk EM, Serrano R, Nanavati D, Swindell EP, Viollet B, O'Halloran TV, Altman JK, Platanias LC. Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on acute myeloid leukemia precursors. Molecular Cancer Therapeutics. 14: 202-12. PMID 25344585 DOI: 10.1158/1535-7163.Mct-14-0665-T  0.309
2014 Eckerdt F, Beauchamp E, Bell J, Iqbal A, Su B, Fukunaga R, Lulla RR, Goldman S, Platanias LC. Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells. Oncotarget. 5: 8442-51. PMID 25193863 DOI: 10.18632/Oncotarget.2319  0.381
2013 Beauchamp EM, Platanias LC. The evolution of the TOR pathway and its role in cancer Oncogene. 32: 3923-3932. PMID 23246968 DOI: 10.1038/Onc.2012.567  0.341
2012 Beauchamp EM, Uren A. A new era for an ancient drug: arsenic trioxide and Hedgehog signaling. Vitamins and Hormones. 88: 333-54. PMID 22391311 DOI: 10.1016/B978-0-12-394622-5.00015-8  0.61
2012 Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW, Glasgow E, Dakshanamurthy S, Lee HS, Daar I, Toretsky JA, Khanna C, Uren A. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene. 31: 269-81. PMID 21706056 DOI: 10.1038/Onc.2011.245  0.66
2011 Bulut G, Fallen S, Beauchamp EM, Drebing LE, Sun J, Berry DL, Kallakury B, Crum CP, Toretsky JA, Schlegel R, Üren A. Beta-catenin accelerates human papilloma virus type-16 mediated cervical carcinogenesis in transgenic mice. Plos One. 6: e27243. PMID 22087269 DOI: 10.1371/Journal.Pone.0027243  0.553
2011 Rahim S, Beauchamp EM, Kong Y, Brown ML, Toretsky JA, Üren A. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. Plos One. 6: e19343. PMID 21559405 DOI: 10.1371/Journal.Pone.0019343  0.642
2011 Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, Peaceman D, Ozdemirli M, Rodriguez O, Macdonald TJ, Albanese C, Toretsky JA, Uren A. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. The Journal of Clinical Investigation. 121: 148-60. PMID 21183792 DOI: 10.1172/Jci42874  0.656
2011 Rahim S, Beauchamp EM, Kong Y, Brown ML, Toretsky JA, Üren A. Abstract 663: YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion Cancer Research. 71: 663-663. DOI: 10.1158/1538-7445.Am2011-663  0.671
2011 Bulut G, Hong S, Chen K, Rahim S, Kosturko GW, Beauchamp EM, Glasgow E, Toretsky JA, Khanna C, Uren A. Abstract 4505: Development of small molecules to target ezrin as anti-metastatic agents Cancer Research. 71: 4505-4505. DOI: 10.1158/1538-7445.Am2011-4505  0.682
2011 Bulut G, Fallen S, Beauchamp EM, Drebing LE, Sun J, Berry DL, Kallakury B, Crum CP, Toretsky JA, Schlegel R, Üren A. Abstract 4328: Beta-catenin accelerates human papillomavirus type16 -E7 mediated cervical carcinogenesis in transgenic mice Cancer Research. 71: 4328-4328. DOI: 10.1158/1538-7445.Am2011-4328  0.556
2010 Beauchamp EM, Rodriguez O, Albanese C, Toretsky JA, Üren A. Abstract 3409: Arsenic trioxide inhibits Ewing sarcoma growth by blocking Hedgehog/GLI pathway Cancer Research. 70: 3409-3409. DOI: 10.1158/1538-7445.Am10-3409  0.644
2009 Golestaneh N, Beauchamp E, Fallen S, Kokkinaki M, Uren A, Dym M. Wnt signaling promotes proliferation and stemness regulation of spermatogonial stem/progenitor cells. Reproduction (Cambridge, England). 138: 151-62. PMID 19419993 DOI: 10.1530/Rep-08-0510  0.579
2009 Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, Matsui W, Endo Y, Rubin JS, Toretsky J, Uren A. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. The Journal of Biological Chemistry. 284: 9074-82. PMID 19189974 DOI: 10.1074/Jbc.M806233200  0.624
2008 Endo Y, Beauchamp E, Woods D, Taylor WG, Toretsky JA, Uren A, Rubin JS. Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells via a Frizzled3- and c-Jun N-terminal kinase-dependent mechanism. Molecular and Cellular Biology. 28: 2368-79. PMID 18212053 DOI: 10.1128/Mcb.01780-07  0.591
Low-probability matches (unlikely to be authored by this person)
2014 Beauchamp EM, Woods BA, Dulak AM, Tan L, Xu C, Gray NS, Bass AJ, Wong KK, Meyerson M, Hammerman PS. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Molecular Cancer Therapeutics. 13: 475-82. PMID 24296828 DOI: 10.1158/1535-7163.Mct-13-0817  0.294
2015 Curi DA, Beauchamp EM, Blyth GT, Arslan AD, Donato NJ, Giles FJ, Altman JK, Platanias LC. Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias. Oncotarget. 6: 33206-16. PMID 26375673 DOI: 10.18632/Oncotarget.5091  0.28
2016 Kosciuczuk EM, Saleiro D, Kroczynska B, Beauchamp EM, Eckerdt F, Blyth GT, Abedin SM, Giles FJ, Altman JK, Platanias LC. Merestinib blocks MNK kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo. Blood. PMID 27307295 DOI: 10.1182/Blood-2016-02-698704  0.273
2015 Sassano A, Mavrommatis E, Arslan AD, Kroczynska B, Beauchamp EM, Khuon S, Chew TL, Green KJ, Munshi HG, Verma AK, Platanias LC. Human Schlafen 5 (SLFN5) Is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells. Molecular and Cellular Biology. 35: 2684-98. PMID 26012550 DOI: 10.1128/Mcb.00019-15  0.259
2022 Saleiro D, Wen JQ, Kosciuczuk EM, Eckerdt F, Beauchamp EM, Oku CV, Blyth GT, Fischietti M, Ilut L, Colamonici M, Palivos W, Atsaves PA, Tan D, Kocherginsky M, Weinberg RS, et al. Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms. Nature Communications. 13: 1750. PMID 35365653 DOI: 10.1038/s41467-022-29381-7  0.257
2014 Wu EJ, Goussetis DJ, Beauchamp E, Kosciuczuk EM, Altman JK, Eklund EA, Platanias LC. Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors. Cancer Biology & Therapy. 15: 473-8. PMID 24496081 DOI: 10.4161/Cbt.27824  0.252
2019 Mishra RK, Clutter MR, Blyth GT, Kosciuczuk EM, Blackburn AZ, Beauchamp EM, Schiltz GE, Platanias LC. Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening. Chemical Biology & Drug Design. PMID 31260185 DOI: 10.1111/Cbdd.13585  0.246
2013 Liao RG, Jung J, Tchaicha J, Wilkerson MD, Sivachenko A, Beauchamp EM, Liu Q, Pugh TJ, Pedamallu CS, Hayes DN, Gray NS, Getz G, Wong KK, Haddad RI, Meyerson M, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Research. 73: 5195-205. PMID 23786770 DOI: 10.1158/0008-5472.Can-12-3950  0.232
2015 Saleiro D, Mehrotra S, Kroczynska B, Beauchamp EM, Lisowski P, Majchrzak-Kita B, Bhagat TD, Stein BL, McMahon B, Altman JK, Kosciuczuk EM, Baker DP, Jie C, Jafari N, Thompson CB, et al. Central role of ULK1 in type I interferon signaling. Cell Reports. 11: 605-17. PMID 25892232 DOI: 10.1016/J.Celrep.2015.03.056  0.226
2013 Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discovery. 3: 1355-63. PMID 24078774 DOI: 10.1158/2159-8290.Cd-13-0310  0.216
2015 Colamonici M, Blyth G, Saleiro D, Szilard A, Bliss-Moreau M, Giles FJ, Altman JK, Beauchamp EM, Platanias LC. Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110a subunit of PI3 kinase Oncotarget. 6: 8062-8070.  0.212
2014 Altman JK, Szilard A, Goussetis DJ, Sassano A, Colamonici M, Gounaris E, Frankfurt O, Giles FJ, Eklund EA, Beauchamp EM, Platanias LC. Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2400-9. PMID 24610825 DOI: 10.1158/1078-0432.Ccr-13-3218  0.209
2012 Beauchamp EM, Platanias LC. BH3 mimetics and multi-kinase inhibition in AML. Blood. 119: 5947-8. PMID 22730522 DOI: 10.1182/Blood-2012-04-420786  0.201
2015 Curi DA, Beauchamp EM, Platanias LC. Overcoming treatment challenges in imatinib-resistant chronic myelogenous leukemia. Leukemia & Lymphoma. 56: 1581-2. PMID 25284498 DOI: 10.3109/10428194.2014.970549  0.066
2015 Ting CS, Dusenbury KH, Pryzant RA, Higgins KW, Pang CJ, Black CE, Beauchamp EM. The Prochlorococcus carbon dioxide-concentrating mechanism: Evidence of carboxysome-associated heterogeneity Photosynthesis Research. 123: 45-60. DOI: 10.1007/s11120-014-0038-0  0.043
2005 Zeyl C, Curtin C, Karnap K, Beauchamp E. Antagonism between sexual and natural selection in experimental populations of Saccharomyces cerevisiae. Evolution; International Journal of Organic Evolution. 59: 2109-15. PMID 16405156 DOI: 10.1111/J.0014-3820.2005.Tb00921.X  0.037
Hide low-probability matches.